PIRFENIDONE
Manufacturer: MAJOR PHARMACEUTICALS
Score: 141.0
Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF). The recommended dosage is 801 mg three times daily, with a titration period of 14 days. Key clinical findings indicate that pirfenidone can reduce the decline in forced vital capacity (FVC) and improve progression-free survival. Important safety information includes warnings about liver enzyme elevations, photosensitivity reactions, and severe cutaneous adverse reactions. Contraindications are not listed, but caution is advised when using pirfenidone with CYP1A2 inhibitors. Dose adjustments may be necessary in patients with liver or renal impairment. Special population considerations include use during pregnancy, pediatric use, and geriatric use, with no established safety and efficacy in pediatric patients and no requirement for dose adjustment based on age.
Liver enzyme elevations, photosensitivity reactions, and severe cutaneous adverse reactions
May be necessary in patients with liver or renal impairment, or when using CYP1A2 inhibitors
801 mg three times daily, with a titration period of 14 days
Not established